Results 31 to 40 of about 3,979 (188)

Exploring Lived Experiences of Men Diagnosed With Prostate Cancer in Oman: A Qualitative Study

open access: yesHealth Expectations, Volume 29, Issue 3, June 2026.
ABSTRACT Background Life after prostate cancer treatment may extend across decades; however, qualitative evidence describing how men in Oman navigate treatment sequelae, disclosure, family involvement, and religious coping remains limited. This study explored the lived experiences of Omani men who had completed primary therapy for prostate cancer ...
Khalood Al‐Abri   +6 more
wiley   +1 more source

Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma [PDF]

open access: yes, 2013
Uveal melanoma is the most common primary intraocular malignancy in adults, with a very high mortality rate due to frequent liver metastases. Consequently, the therapy of uveal melanoma remains a major clinical challenge and new treatment approaches are ...
Block, Norman L   +11 more
core   +1 more source

Effects of an LHRH agonist on endocrine function, LHRH receptor and LH/hCG receptor in the pituitary-gonadal axis of male rats

open access: yesEndocrinologia Japonica, 1986
The effects of an LHRH agonist (LHRHa), [D-Ser (tBu)]6 des-Gly-NH210) ethylamide, on endocrine function and the LHRH and LH/hCG receptors in the pituitary-gonadal axis were examined. The LHRHa was injected at 100 ng/100 g body weight into male rats once a day for 4 weeks and its effects were observed until 2 weeks after the end of treatment.
KOMATSU, MACHIKO   +2 more
openaire   +4 more sources

Phase II Randomized Study of MK‐2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG‐ACRIN E2809)

open access: yesThe Prostate, Volume 86, Issue 6, Page 697-709, May 2026.
ABSTRACT Background Combined inhibition of AKT and the androgen receptor (AR) might be more efficacious than AR inhibition alone in biochemical recurrence (BCR) of prostate cancer (PC) by additive effects on the two effector pathways. Patients and Methods E2809 assigned 108 high‐risk BCR patients (1:1, arm‐A: arm‐B) to two phases with 4‐week cycles ...
Anna C. Ferrari   +12 more
wiley   +1 more source

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation

open access: yesThe Prostate, Volume 86, Issue 6, Page 727-731, May 2026.
ABSTRACT Background Methyl Methanesulfonate‐Sensitivity Protein 22‐Like (MMS22L) plays a key role in homology‐directed DNA repair, and experimental models have shown that its loss confers sensitivity to Poly (ADP‐ribose) polymerase inhibitors (PARPi).
Mayuko Kanayama   +12 more
wiley   +1 more source

Impact of Hormonal and Radiation Therapy on Bladder Outlet Obstruction in High‐Risk Localized Prostate Cancer: A Prospective Pressure‐Flow Study

open access: yesInternational Journal of Urology, Volume 33, Issue 5, May 2026.
ABSTRACT Purpose There are few reports investigating urodynamic changes after radiotherapy and hormonal therapy (HT) for prostate cancer. We prospectively evaluated differences in bladder outlet obstruction (BOO) using pressure‐flow studies (PFS) before and after HT and radiotherapy in patients with high‐risk localized or locally advanced prostate ...
Yuki Kyoda   +7 more
wiley   +1 more source

Oncologic Outcomes of Cytoreductive Radical Prostatectomy in Patients With Synchronous Metastatic Castration‐Sensitive Prostate Cancer: A Retrospective Analysis

open access: yesCancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Objectives Local therapy for metastatic castration‐sensitive prostate cancer (mCSPC) remains controversial. This study aimed to assess the feasibility, safety, and oncologic outcomes of cytoreductive radical prostatectomy (cRP) in patients with synchronous mCSPC, with a particular focus on pathological findings.
Kento Morozumi   +8 more
wiley   +1 more source

Hypothalamic alpha adrenergic receptors and the regulation of LHRH release [PDF]

open access: yes, 1990
The neurotransmitter system regulating the release of luteinizing hormone releasing hormone (LHRH) has been actively investigated since the classic 1947 work of Sawyer.
Gitzen, James Francis
core  

Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats [PDF]

open access: yes, 2004
Our previous studies showed that treatment of female rats with large doses of Cetrorelix, an antagonist of luteinizing hormone-releasing hormone (LHRH), reduces levels of serum LH, estradiol, progesterone, and the concentration of pituitary LHRH ...
Toller, Gabor L   +4 more
core   +1 more source

Cerebellar Cystic Metastasis—An Unusual Presentation of Prostate Adenocarcinoma Dissemination: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Although prostate cancer is among the most common malignant tumors in men, brain metastases from prostatic cancer are infrequent. Brain dissemination is especially rare with the most frequent histological type of prostatic adenocarcinoma. We present a case of a cystic‐hemorrhagic cerebellar metastasis with a solid enhancing component in a ...
Mia Smoljan Basuga   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy